Glenmark gets Russian health ministry's nod to market allergic rhinitis tablets

Drug firm Glenmark Pharmaceuticals on Monday said it has received approval from the Ministry of Healthcare, Russia, to market Montlezir film-coated tablets used for treatment of allergic rhinitis. Montlezir is expected to be available in the Russian market in third quarter of financial year 2019-20, Glenmark said in a BSE filing. "Russia is one of the key markets for us and we are consistently looking to expand our product portfolio," Glenmark Pharmaceuticals Senior Vice President and Head - Asia, Russia and CIS region Csaba Kantor said. Glenmark has built strong capabilities in the respiratory space and is among the leading players in this therapy area across several markets globally, he added. According to IQVIA, in the respiratory space, Glenmark continues to secure a strong position and ranked fourth amongst the companies present in the expectorants market in Russia as of MAT July 2019, the company said.

Upload Company Info



Chemxpert Demo Video


Dataset Sample


Chemical Name

Synonyms

Molecular Formula

Molecular Weight


To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Innovator

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Market Status

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Indication

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Therapeutic Segment

To Access this information please pay by using "Pay & Download" button.

Pay & Download

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Thank you for your enquiry

Your product will be updated soon in our database


Submit Your Query



Select Any Option



Page loaded in 0.001056 seconds